NOEL REYES MATA, PETITIONER,
v.
ERIC H. HOLDER, JR., ATTORNEY GENERAL.
NOEL REYES MATA, PETITIONER,
ERIC H. HOLDER, JR., ATTORNEY GENERAL.
135 S. Ct. 1039
Supreme Court of the United States (2015)
Positive Treatment
Also reported at: 190 L. Ed. 2d 907
Cited by 14 cases
Opinion
Full opinion text not available for this case.
Cases With Similar Vibessemantic neighbors from the corpus
Citator
Cited By
-
United States v. Sineneng-Smith, 140 S. Ct. 1575 (U.S. 2020)…0 U.S. ----, 137 S.Ct. 461, 196 L.Ed.2d 339 (2016) ; Green v. Brennan , 576 U.S. 1087, 136 S.Ct. 14, 192 L.Ed.2d 983 (2015) ; Reyes Mata v. Lynch, 576 U.S. 143, 135 S.Ct. 2150, 192 L.Ed.2d 225, reported sub nom. Reyes Mata v. Holder , 574 U.S. 1118, 135 S.Ct. 1039, 190 L.Ed.2d 907 (2015) ; and to address the Court's jurisdiction to decide the question presented, Montgomery v. Louisiana , 575 U.S. 933, 135 S.Ct. 1729, 191 L.Ed.2d (2015). For violations of 8 U.S.C. § 1324(a)(1)(A)(iv), the prison term is "not…
-
Mata v. Lynch, 135 S. Ct. 2150 (U.S. 2015)…s has affirmed its jurisdiction to decide an appeal, like Mata's, that seeks equitable tolling of the statutory time limit to file a motion to reopen a removal proceeding.We granted certiorari to resolve this conflict. 574 U.S. ----, 135 S.Ct. 1039, 190 L.Ed.2d 907 (2015). And because the Federal Government agrees with Mata that the Fifth Circuit had jurisdiction over his appeal, we appointed an amicus curiaeto defend the judgment below.We now reverse. II As we held in Kucana v. Holder,circuit courts have ju…1 / 2
-
McFADDEN v. United States, 135 S. Ct. 2298 (U.S. 2015)…ourt concluded that the "intent element [in the Act] requires [only] that the government prove that the defendant meant for the substance at issue to be consumed by humans." Id.,at 441; see id.,at 444. We granted a writ of certiorari, 574 U.S. ----, 135 S.Ct. 1039, 190 L.Ed.2d 908 (2015), and now vacate the judgment of the Court of Appeals and remand. II A The Analogue Act requires a controlled substance analogue, if intended for human consumption, to be treated "as a controlled substance in schedule I" for p…
Previewing 3 of 4 citing cases — full citator treatment, depth of discussion, and citing context are member features.
Join FLexlaw to unlock all legal intelligence